Blackburn-headquartered EG Group has further backed Hydrogen Vehicle Systems following a £5m investment last year
Blackburn billionaire Issa brothers' petrol station and retail giant firm EG Group has pledged to invest £25m in a zero-emission vehicles firm.
HVS chief executive Jawad Khursheed said: "We are proud to be providing the solution of state-of-the art technology, design, efficiency within hydrogen vehicles. We are leading in the Net Zero target, providing the logistics industry with a pioneering vehicle that will give range, comfort and a greener drive."
The investment in HVS last year was provided by Beehive Equity Limited, a wholly-owned subsidiary of EG Group. In a statement, EG Group commercial director Ilyas Munshi said: "We are committed to driving sustainability across our extensive UK and global fuel forecourt network by investing in HVS trucks, influencing the demand for hydrogen and vehicles in parallel from our large selection of partnerships.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study) - BMC MedicineBackground In vitro drug screening studies have indicated that camostat mesilate (FOY-305) may prevent SARS-CoV-2 infection into human airway epithelial cells. This study was conducted to investigate whether camostat mesilate is an effective treatment for SARS-CoV-2 infection (COVID-19). Methods This was a multicenter, double-blind, randomized, parallel-group, placebo-controlled study. Patients were enrolled if they were admitted to a hospital within 5 days of onset of COVID-19 symptoms or within 5 days of a positive test for asymptomatic patients. Severe cases (e.g., those requiring oxygenation/ventilation) were excluded. Patients were enrolled, randomized, and allocated to each group using an interactive web response system. Randomization was performed using a minimization method with the factors medical institution, age, and underlying diseases (chronic respiratory disease, chronic kidney disease, diabetes mellitus, hypertension, cardiovascular diseases, and obesity). The patients, investigators/subinvestigators, study coordinators, and other study personnel were blinded throughout the study. Patients were administered camostat mesilate (600 mg qid; four to eight times higher than the clinical doses in Japan) or placebo for up to 14 days. The primary efficacy endpoint was the time to the first two consecutive negative tests for SARS-CoV-2. Results One-hundred fifty-five patients were randomized to receive camostat mesilate (n = 78) or placebo (n = 77). The median time to the first test was 11.0 days (95% confidence interval [CI]: 9.0–12.0) in the camostat mesilate group and 11.0 days (95% CI: 10.0–13.0) in the placebo group. Conversion to negative viral status by day 14 was observed in 45 of 74 patients (60.8%) in the camostat mesilate group and 47 of 74 patients (63.5%) in the placebo group. The primary (Bayesian) and secondary (frequentist) analyses found no significant differences in the primary endpoint between the two groups. No additional safety concerns be
Consulte Mais informação »
US campaign group criticizes unfair software licensingUS campaign group forms as customers complain of lock-in, unclear terms, problems using wares in cloud
Consulte Mais informação »
Shell acquires Nigerian renewables group in first African power deal\n\t\t\tExpert insights, analysis and smart data help you cut through the noise to spot trends,\n\t\t\trisks and opportunities.\n\t\t\n\t\tJoin over 300,000 Finance professionals who already subscribe to the FT.
Consulte Mais informação »
US group to fight Scotland's abortion buffer zones40 Days for Life backs protests outside clinics and will help mount a legal challenge if a new law is passed.
Consulte Mais informação »